Which Cherry, and which entity extends the credit?
This profile concerns the Cherry financing platform at withcherry.com. Cherry identifies itself as a technology provider, not a bank or lender. Its listed licensed entities include Cherry Technologies Inc., Cherry Payments LLC, Cherry LLC and Cherry Retail Installment LLC. Its financing-partner disclosure says all loans through the platform are made by Lead Bank, Member FDIC; retail installment sales contracts are extended by unaffiliated merchants. Cherry may purchase interests in, purchase, or service those obligations as applicable. [1]
Analysis: the distinction is fundamental. A bank loan funds a customer’s purchase; a retail installment contract begins as the seller’s credit sale. A platform can organize the application and collect payments in either arrangement. Neither the brand nor the payment portal, by itself, identifies the legal creditor.
Product ranges and actual customer obligations
Cherry’s current financing disclosures describe 0%–35.99% , terms from 1–60 months and amounts from $35–$65,000, subject to eligibility. They specifically qualify the advertised 90% approval rate as applying to Pay-in-4 loans. These ranges do not mean every applicant qualifies for the maximum amount, longest term or 0% offer. [1]
The consumer FAQ describes a soft application check and reporting of a confirmed plan to credit bureaus. It says a 0% promotional rate can change prospectively after without retroactive interest. Early repayment carries no penalty; credit-card payments incur a 2.99% processing fee. Late or insufficient-funds fees can apply under the customer’s state and agreement. A down payment is separate from the stated number of monthly payments. [2]
Analysis: “no hard check” is an application-process description, not a promise that repayment cannot affect credit. Similarly, a qualifying 0% offer is different from a revolving medical card with . The full payment schedule and default provisions remain important even when the initial interest rate is zero.
Provider economics are contract-based
The April 15, 2026 seller agreement identifies Cherry Technologies, Inc. as program manager providing administrative and technical services. A transaction fee is deducted from funding. It permits a risk adjustment for prohibited second-look placement and charges for certain disputes, refunds or . Merchant representations address genuine purchases, delivery and service performance; shifting repayment collection does not remove those obligations. [3]
Cherry’s business page advertises merchant fees starting at 1.7%–1.9%, while saying actual tiers vary by plan and business volume. It also advertises use by 60,000 providers. These are company marketing statements reviewed in October 2026, not a disclosed average fee, independently audited active-provider count or measured share of healthcare financing. [4]
Analysis: a provider is exchanging some economics for faster payment and an external repayment process. The trade-off depends on whether treatment acceptance truly increases, whether the service is completed and whether the financing displaces a cheaper in-house arrangement. A high financed ticket is not automatically an increase in the provider’s total sales.
The separate merchant-contract route
Cherry’s February 3, 2026 retail installment purchase agreement names Cherry Technologies or specified affiliates as potential buyers. It defines the purchase price as the amount owed excluding finance charges, less a transaction fee. The customer’s contract is initially with the seller and is offered for assignment. This is separate from describing Lead Bank as originator of a loan. [5]
A September 25, 2026 split-funding agreement describes Cherry’s platform, a Cherry merchant and a provider receiving funds at the merchant’s direction; it expressly identifies Lead Bank as the banking partner. Multiple service participants and a split payout do not mean multiple independent consumer credit approvals. [6]
Analysis: these arrangements make settlement accuracy and accountability especially important. A patient may experience one purchase while the financing system allocates proceeds among several participants. Contract ownership, servicing responsibility and the underlying service obligation therefore need to remain distinguishable.
Adoption and approval claims have limited denominators
Cherry’s references page says the roughly 90% approval claim is with Pay-in-4 enabled. Some other comparisons use Q1 2025 average approvals with Pay in 4 enabled, while a satisfaction score is sourced to internal Q2 2023 data. The page also labels individual provider results. These are different periods and populations, not a single current independently verified dataset. [7]
Analysis: an approval statistic may include a short, smaller offer rather than the treatment amount or repayment term originally sought. It does not disclose take-up, funded dollars, performance or whether the patient ultimately received the service. Provider count likewise does not establish transaction activity per location. This profile therefore makes no estimate of Cherry’s revenue, valuation, market share, profitability or portfolio loss rate.
Funding and underwriting: what is visible and what is not
Analysis: the disclosed bank-origination and contract-purchase structures establish the possible movement of receivables, but they do not establish Cherry’s complete funding stack. The reviewed public materials do not provide an audited balance sheet, an average funding cost, the percentage of receivables retained, or comprehensive loss . A private-company operating model can be explained without filling those gaps with an invented financial model.
For customers, Cherry describes eligibility using credit history, income, expenses and other information. [1]
Analysis: those inputs are consistent with a repayment-capacity decision, but the public description does not reveal approval cutoffs, validation results, or the economics of a marginal approval. A broad eligibility message is not a substitute for those measurements.
Medical financing adds a distinct consumer-protection issue
The CFPB’s May 2023 medical-financing report describes risks from promoting third-party credit at the point of care, including financial burdens and transparency concerns. It is an industry report, not an enforcement finding against Cherry. [8]
Analysis: a patient may interpret a financing option presented in a treatment setting as part of the provider’s care recommendation. The clinical decision and the credit decision serve different purposes. Available insurance, financial assistance, treatment alternatives and a loan’s cost can materially change the outcome; loan approval does not determine medical necessity or affordability.
Cherry’s FAQ says refunds generally begin with the provider, with a dispute route available when resolution fails; partial refunds adjust the balance without changing the monthly payment amount. [2] Analysis: a cancelled or contested procedure therefore creates both a service issue and a credit-servicing issue. Accurate reconciliation matters even when everyone initially agreed to the loan.
A transparent provider illustration and the evidence boundary
Illustration: on a hypothetical $3,000 financed service, an assumed 5% merchant fee is $150, leaving $2,850 before other adjustments. At a 40% contribution margin before financing, a genuinely additional $3,000 service contributes $1,200 and $1,050 after that fee. If the same service would have been paid by another method anyway, the incremental revenue is zero and the financing cost must be compared with that alternative. These are hypothetical figures, not Cherry pricing.
Analysis: the business case and the patient outcome can diverge. More accepted treatment may help a provider while still increasing a household’s repayment burden. Evidence that would materially improve this profile includes consistently defined active-provider and funding data, independently supported customer outcomes, mature repayment cohorts, and public disclosure of funding and risk retention. Until then, promotional claims remain attributed and financial conclusions remain bounded.
Sources
- Cherry — financing partners, entities and product disclosuresSourceBack to text: ↑1↑2↑3
- Cherry — consumer FAQ, fees, credit reporting and refundsSourceBack to text: ↑1↑2
- Cherry — seller purchase financing participation agreement, April 15, 2026SourceBack to text: ↑
- Cherry — provider pricing and adoption marketingSourceBack to text: ↑
- Cherry — retail installment contract purchase agreement, February 3, 2026SourceBack to text: ↑
- Cherry — split-funding participation agreement, September 25, 2026SourceBack to text: ↑
- Cherry — references and qualifications for company claimsSourceBack to text: ↑
- CFPB — medical credit cards and financing plans, May 4, 2023Official sourceBack to text: ↑